Clinical Trial Update: Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

This Phase 1 trial update reports safety and immunogenicity data for a recombinant DNA and adenovirus expressing the L523S protein in patients with early-stage …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• L523S recombinant DNA and adenovirus vector expressing L523S protein (recombinant DNA and adenovirus expressing L523S protein)

Snippet

Sponsor: Corixa Corporation | Conditions: Non-Small Cell Lung Cancer | Phase 1 | Status: UNKNOWN